All Articles

Explore the unique challenges faced by young patients with breast cancer and learn how innovative navigation programs are bridging gaps in care and empowering patients to thrive.

The Impact of Underutilizing Adjuvant CDK4/6 Inhibitors in Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer

We are pleased to announce a new 2-part series, Did You Know? Beyond the Data. This article, with video commentary by Hope Rugo, MD, and an accompanying infographic, provides the latest clinical data and real-world evidence for consideration when treating early breast cancer patients with high risk of recurrence. We invite you to explore this informative series, designed to empower healthcare professionals with actionable insights to improve patient outcomes.

A Dose-Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series

Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study

By Jamie Carroll, APRN, CNP, MSN

Interview with the Innovators

In this sixth installment, Ms Carroll discusses the TRADE study with abemaciclib and emphasizes the importance of individualized patient care, clear communication about dosing goals, and teamwork among healthcare providers to implement dose escalation effectively. This strategy aims to address patient concerns about side effects while ensuring adherence to the full treatment plan.

A Dose-Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series

Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care

By Jamie Carroll, APRN, CNP, MSN

Interview with the Innovators

In this fifth installment, Ms Carroll discusses strategies for managing adverse events associated with abemaciclib, emphasizing the importance of patient involvement and personalized care. She underscores the value of maintaining open communication and regular touchpoints with patients to address concerns, build trust, and ensure adherence to therapy. These strategies aim to improve the quality of life for patients on abemaciclib.

What Is Special About Oncology Navigation Professionals?

By Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

The Editor’s Take

What makes oncology navigation professionals stand out? Their patient-centered approach bridges the gap between individuals and the complex healthcare system, addressing barriers and enhancing care coordination.

Addressing Barriers to Timely Cancer Care Through Patient Navigation and Mobile Technology

By Timothy Mullett, MD, MBA, FACS; Pamela Hull, PhD; Ming-Yuan Chih, PhD; Joseph Alexander III, MHA, MS, PMP; Christine Stroebel, MPH; Joan Scales, LCSW, OSW-C; Katie Brown, MSSW, CSW; Charles McCann III; Jennifer Zhu, MS; Emma Wickland, MPH, CHES; Krista Casazza, PhD, RD, CSSD; Marcie S. Wright, PhD, MPH; Robert A. Winn, MD

Health Equity

The Comprehensive Connected Cancer Care (C4) Program is redefining patient support by combining mobile technology with personalized navigation services. Learn how this app connects patients to trusted resources, monitors their needs, and bridges gaps in care.

Navigation Refresh: Implementing Oncology Navigation Programs

By Mandi L. Pratt-Chapman, PhD, MA, HON-OPN-CG

Navigation

Explore actionable guidance for establishing and refining oncology navigation programs, from identifying patient needs to evaluating program success.

Patient Navigation Takes Center Stage in the Philippines

By Maricar R. Sabeniano, MD

Navigation

From its grassroots beginnings to its recognition as a national healthcare priority, explore how patient navigation in the Philippines has become a cornerstone of equitable cancer care.

Oncology Nurses’ Perceptions of Participation in Clinical Trials Among Patients With Developmental Disabilities

By Heather Becker, PhD; Carolyn Phillips, PhD, MSN, RN; Irina Haack, MSN, RN; Sabrina Q. Mikan, PhD, RN, ACNS-BC

Original Research

Despite the essential role of clinical trials in advancing cancer treatments, patients with developmental disabilities remain underrepresented. A groundbreaking study reveals how navigators and healthcare providers can make trials more accessible for all.

A Dose-Escalation Strategy for HR+/HER2− Early Breast Cancer: An Educational Video Series

Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes

By Heather Moore, PharmD, BCOP, CPP

Interview with the Innovators

In this fourth installment, Dr Moore shares strategies for optimizing abemaciclib treatment through dose escalation and proactive toxicity management. She emphasizes patient education on managing common side effects and highlights the importance of ongoing patient engagement through touchpoints and clear communication to ensure successful treatment outcomes.

All Articles

Page 3 of 281

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.